Patents by Inventor Ryo TSUMURA
Ryo TSUMURA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230340176Abstract: Provided is a method for producing hollow resin particles in which a residual amount of a hydrocarbon solvent once held inside particles in a production process is reduced and particle breakage is suppressed. The method for producing hollow resin particles, which include preparing a mixture liquid containing a polymerizable monomer, a hydrocarbon solvent, a polymerization initiator and an aqueous medium, suspending the mixture liquid to prepare a suspension, subjecting the suspension to a polymerization reaction to prepare a precursor composition containing precursor particles having a hollow portion and including the hydrocarbon solvent in the hollow portion, and removing the hydrocarbon solvent from the precursor particles, wherein the polymerizable monomer contains a crosslinkable monomer in an amount of from 40% by mass to 100% by mass, and wherein the removal of the hydrocarbon solvent is performed by a specific method.Type: ApplicationFiled: February 25, 2021Publication date: October 26, 2023Applicant: ZEON CORPORATIONInventor: Ryo Tsumura
-
Patent number: 11377504Abstract: The present invention provides an antibody beneficial for treatment of a solid tumor, an antibody-drug conjugate thereof, and an anticancer agent comprising these. The present invention provides, for example, an antibody that binds to tissue factor or an antigen-binding fragment thereof, wherein the antibody has a dissociation rate constant kd of 5×10?4 s?1 or more and an association rate constant Ka of 1×104 M?1 s?1 or more.Type: GrantFiled: October 29, 2018Date of Patent: July 5, 2022Assignees: National Cancer Center Japan, RIN Institute Inc.Inventors: Yasuhiro Matsumura, Masahiro Yasunaga, Shinji Saijo, Ryo Tsumura
-
Publication number: 20210221911Abstract: The present invention provides an antibody beneficial for treatment of a solid tumor, an antibody-drug conjugate thereof, and an anticancer agent comprising these. The present invention provides, for example, an antibody that binds to tissue factor or an antigen-binding fragment thereof, wherein the antibody has a dissociation rate constant kd of 5×10?4 s?1 or more and an association rate constant Ka of 1×104 M?1s?1 or more.Type: ApplicationFiled: October 29, 2018Publication date: July 22, 2021Applicants: National Cancer Center Japan, RIN Institute Inc.Inventors: Yasuhiro MATSUMURA, Masahiro YASUNAGA, Shinji SAIJO, Ryo TSUMURA
-
Patent number: 10386739Abstract: The present invention is to provide a toner production method configured to prevent scale formation, be resistant to pipe clogging, and realize stable and efficient toner production, even in the case of long-term continuous production. Disclosed is a toner production method comprising: a dispersing step for obtaining a colorant dispersion by, in a stirring tank, (a) dispersing or dissolving a colorant and a charge control agent in a polymerizable monomer, or (b) dispersing or dissolving a binder resin, a colorant and a charge control agent in an organic solvent, and a droplets forming step by suspending the colorant dispersion in an aqueous dispersion medium, wherein, in the dispersing step, the binder resin, colorant or charge control agent is added to the polymerizable monomer or organic solvent in the stirring tank, from a hopper, through a pipe heated by a heating device.Type: GrantFiled: April 4, 2018Date of Patent: August 20, 2019Assignee: ZEON CORPORATIONInventors: Ryo Tsumura, Junichi Takashima, Fuminari Oyama
-
Publication number: 20190041764Abstract: The positively-chargeable black toner includes colored resin particles containing a binder resin, carbon black and, as a charge control resin, a quaternary ammonium salt group-containing copolymer, wherein the quaternary ammonium salt group-containing copolymer is a styrene acrylic polymer containing a quaternary ammonium salt group-containing (meth)acrylate monomer unit; wherein a copolymerization ratio of the quaternary ammonium salt group-containing (meth)acrylate monomer in the quaternary ammonium salt group-containing copolymer, is in a range of from 0.1% by mass to 2.5% by mass. A content of the carbon black is in a range of from 10 parts by mass to 15 parts by mass with respect to 100 parts by mass of the binder resin. A blow-off charge amount of the colored resin particles measured by a specific charge amount measuring method, is in a range of from 5 ?C/g to 60 ?C/g.Type: ApplicationFiled: March 24, 2017Publication date: February 7, 2019Applicant: ZEON CORPORATIONInventor: Ryo Tsumura
-
Publication number: 20180292764Abstract: The present invention is to provide a toner production method configured to prevent scale formation, be resistant to pipe clogging, and realize stable and efficient toner production, even in the case of long-term continuous production. Disclosed is a toner production method comprising: a dispersing step for obtaining a colorant dispersion by, in a stirring tank, (a) dispersing or dissolving a colorant and a charge control agent in a polymerizable monomer, or (b) dispersing or dissolving a binder resin, a colorant and a charge control agent in an organic solvent, and a droplets forming step by suspending the colorant dispersion in an aqueous dispersion medium, wherein, in the dispersing step, the binder resin, colorant or charge control agent is added to the polymerizable monomer or organic solvent in the stirring tank, from a hopper, through a pipe heated by a heating device.Type: ApplicationFiled: April 4, 2018Publication date: October 11, 2018Applicant: ZEON CORPORATIONInventors: Ryo Tsumura, Junichi Takashima, Fuminari Oyama
-
Patent number: 9920133Abstract: Monoclonal antibodies against human and mouse tissue factor, and fragments thereof, are disclosed, as well as pharmaceutical compositions and compositions for drug delivery containing the same. Therapeutic methods using the same are also disclosed.Type: GrantFiled: February 3, 2015Date of Patent: March 20, 2018Assignees: NATIONAL CANCER CENTER, The University of Tokyo, RIKEN, NanoCarrier Co., Ltd.Inventors: Yasuhiro Matsumura, Masahiro Yasunaga, Yoshikatsu Koga, Yoshiyuki Yamamoto, Ryuta Sato, Ryo Tsumura, Kazunori Kataoka, Nobuhiro Nishiyama, Yutaka Miura, Shino Manabe, Yasuki Kato
-
Publication number: 20170094467Abstract: A direction indicating device according to an embodiment includes: an orientation sensor that detects an orientation; a wireless communication device that receives orientation information; and a light emitting device. Furthermore, the direction indicating device includes a processor that controls the direction of light, generated by the light emitting device, in accordance with the angle that is formed by the detected orientation and the direction that is indicated by the received orientation information.Type: ApplicationFiled: September 1, 2016Publication date: March 30, 2017Applicant: FUJITSU LIMITEDInventors: Keisuke KIUCHI, Hiroyuki Kawahara, Tatsuhiro SATO, Ryo Tsumura, Masahiro Tsukahara, Atsuji SEKIGUCHI, Yoshinobu Iwasato
-
Publication number: 20160333113Abstract: Monoclonal antibodies against human and mouse tissue factor, and fragments thereof, are disclosed, as well as pharmaceutical compositions and compositions for drug delivery containing the same. Therapeutic methods using the same are also disclosed.Type: ApplicationFiled: February 3, 2015Publication date: November 17, 2016Applicants: NATIONAL CANCER CENTER, The University of Tokyo, RIKEN, NanoCarrier Co., Ltd.Inventors: Yasuhiro MATSUMURA, Masahiro YASUNAGA, Yoshikatsu KOGA, Yoshiyuki YAMAMOTO, Ryuta SATO, Ryo TSUMURA, Kazunori KATAOKA, Nobuhiro NISHIYAMA, Yutaka MIURA, Shino MANABE, Yasuki KATO